Maternal and Fetal Research Unit, Division of Reproduction and Endocrinology, King's College London, St Thomas' Hospital Campus, London, UK.
J Cell Mol Med. 2011 Mar;15(3):577-86. doi: 10.1111/j.1582-4934.2010.01021.x.
Premature birth accounts for approximately 75% of neonatal mortality and morbidity in the developed world. Despite this, methods for identifying and treating women at risk of preterm labour are limited and many women still present in preterm labour requiring tocolytic therapy to suppress uterine contractility. The aim of this study was to assess the utility of Kv7 channel activators as potential uterine smooth muscle (myometrium) relaxants in tissues from pregnant mice and women. Myometrium was obtained from early and late pregnant mice and from lipopolysaccharide (LPS)-injected mice (day 15 of gestation; model of infection in pregnancy). Human myometrium was obtained at the time of Caesarean section from women at term (38-41 weeks). RT-PCR/qRT-PCR detected KCNQ and KCNE expression in mouse and human myometrium. In mice, there was a global suppression of all KCNQ isoforms, except KCNQ3, in early pregnancy (n= 6, P < 0.001 versus late pregnant); expression subsequently increased in late pregnancy (n= 6). KCNE isoforms were also gestationally regulated (P < 0.05). KCNQ and KCNE isoform expression was slightly down-regulated in myometrium from LPS-treated-mice versus controls (P < 0.05, n= 3-4). XE991 (10 μM, Kv7 inhibitor) significantly increased spontaneous myometrial contractions in vitro in both human and mouse myometrial tissues (P < 0.05) and retigabine/flupirtine (20 μM, Kv7 channel activators) caused profound myometrial relaxation (P < 0.05). In summary, Kv7 activators suppressed myometrial contraction and KCNQ gene expression was sustained throughout gestation, particularly at term. Consequently, activation of the encoded channels represents a novel mechanism for treatment of preterm labour.
早产约占发达国家新生儿死亡和发病的 75%。尽管如此,用于识别和治疗有早产风险的女性的方法仍然有限,许多女性仍处于早产,需要使用宫缩抑制剂来抑制子宫收缩。本研究旨在评估 Kv7 通道激活剂作为潜在的子宫平滑肌(子宫肌)松弛剂在妊娠小鼠和女性组织中的效用。从妊娠早期和晚期的小鼠以及脂多糖(LPS)注射的小鼠(妊娠第 15 天;妊娠感染模型)中获得子宫肌。从足月剖宫产的女性(38-41 周)获得人子宫肌。RT-PCR/qRT-PCR 检测了小鼠和人子宫肌中 KCNQ 和 KCNE 的表达。在小鼠中,除 KCNQ3 外,所有 KCNQ 同工型在妊娠早期(n=6,P<0.001 与妊娠晚期相比)均受到全面抑制;随后在妊娠晚期(n=6)表达增加。KCNE 同工型也受到妊娠调节(P<0.05)。与对照组相比,LPS 处理的小鼠子宫肌中的 KCNQ 和 KCNE 同工型表达略有下调(P<0.05,n=3-4)。XE991(10 μM,Kv7 抑制剂)在体外显著增加了人源和鼠源子宫肌组织的自发性子宫肌收缩(P<0.05),瑞替加滨/氟鲁替尼(20 μM,Kv7 通道激活剂)导致子宫肌明显松弛(P<0.05)。综上所述,Kv7 激活剂抑制了子宫肌收缩,KCNQ 基因表达在整个妊娠期间持续存在,特别是在足月时。因此,激活编码通道代表了治疗早产的一种新机制。